KR101620642B1 - 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물 - Google Patents

항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR101620642B1
KR101620642B1 KR1020107012374A KR20107012374A KR101620642B1 KR 101620642 B1 KR101620642 B1 KR 101620642B1 KR 1020107012374 A KR1020107012374 A KR 1020107012374A KR 20107012374 A KR20107012374 A KR 20107012374A KR 101620642 B1 KR101620642 B1 KR 101620642B1
Authority
KR
South Korea
Prior art keywords
antibody
expression
subject
sample
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107012374A
Other languages
English (en)
Korean (ko)
Other versions
KR20100095564A (ko
Inventor
데이비드 도난
바트 버링톤
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20100095564A publication Critical patent/KR20100095564A/ko
Application granted granted Critical
Publication of KR101620642B1 publication Critical patent/KR101620642B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020107012374A 2007-11-07 2008-11-07 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물 Active KR101620642B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98627707P 2007-11-07 2007-11-07
US60/986,277 2007-11-07

Publications (2)

Publication Number Publication Date
KR20100095564A KR20100095564A (ko) 2010-08-31
KR101620642B1 true KR101620642B1 (ko) 2016-05-12

Family

ID=40377361

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012374A Active KR101620642B1 (ko) 2007-11-07 2008-11-07 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물

Country Status (11)

Country Link
US (1) US9068230B2 (enExample)
EP (1) EP2222875B1 (enExample)
JP (2) JP5730576B2 (enExample)
KR (1) KR101620642B1 (enExample)
CN (1) CN101910414B (enExample)
AU (1) AU2008323701B2 (enExample)
BR (1) BRPI0820707A2 (enExample)
CA (1) CA2704499C (enExample)
IL (1) IL205391A (enExample)
MX (1) MX2010005080A (enExample)
WO (1) WO2009062125A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9075066B2 (en) * 2008-04-21 2015-07-07 Korea Research Institute Of Bioscience And Biotechnology CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
GB2483810B (en) 2008-11-07 2012-09-05 Sequenta Inc Methods for correlating clonotypes with diseases in a population
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
PT2387627E (pt) 2009-01-15 2016-06-03 Adaptive Biotechnologies Corp Determinação do perfil de imunidade adaptativa e métodos de geração de anticorpos monoclonais
US9617600B2 (en) 2009-04-18 2017-04-11 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
JP2012531202A (ja) 2009-06-25 2012-12-10 フレッド ハチンソン キャンサー リサーチ センター 適応免疫を測定する方法
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
CN103502472B (zh) 2011-02-28 2017-06-06 弗·哈夫曼-拉罗切有限公司 生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
US8592156B2 (en) * 2011-08-08 2013-11-26 Roche Molecular Systems, Inc. Predicting response to anti-CD20 therapy in DLBCL patients
WO2013036459A2 (en) * 2011-09-09 2013-03-14 Sequenta, Inc. Sequence-based measures of immune response
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (en) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS
AU2012347460B2 (en) 2011-12-09 2017-05-25 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
JP6302847B2 (ja) 2012-03-05 2018-03-28 アダプティヴ バイオテクノロジーズ コーポレーション 頻度が一致したサブユニットからの、対をなす免疫受容体鎖の決定
ES2711156T3 (es) 2012-05-08 2019-04-30 Adaptive Biotechnologies Corp Método para medir y calibrar el sesgo de amplificación en reacciones de PCR multiplexadas
EP2904111B1 (en) 2012-10-01 2017-12-06 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
ES2923942T3 (es) * 2013-11-06 2022-10-03 Us Health Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión
US20170292149A1 (en) 2014-03-05 2017-10-12 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
MA39804A (fr) * 2014-03-27 2017-02-01 Hoffmann La Roche Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
ES2777529T3 (es) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células
WO2016069886A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corporation Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
AU2015339128C1 (en) 2014-10-29 2021-12-16 Seagen Inc. Dosage and administration of non-fucosylated anti-CD40 antibodies
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
CA2968543C (en) 2014-11-25 2024-04-02 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
WO2016138122A1 (en) 2015-02-24 2016-09-01 Adaptive Biotechnologies Corp. Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing
WO2016161273A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
EP3329244B1 (en) 2015-07-30 2022-10-05 Qiagen GmbH Method of preparing a frozen biological sample
ES2885476T3 (es) * 2015-10-05 2021-12-13 Ucb Biopharma Sprl Firmas moleculares para uso en diagnóstico y análisis de respuesta al tratamiento de enfermedades autoinmunes
CN109414451B (zh) * 2016-05-16 2022-08-12 德克萨斯大学系统董事会 用于作为纳米粒递送tRNA的组合物及其使用方法
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
CA3053358A1 (en) 2017-04-04 2018-10-11 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2022120038A1 (en) * 2020-12-02 2022-06-09 Albert Einstein College Of Medicine Method for predicting patient response to cd40-targeted therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044294A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Method of therapy for cancers expressing the cd40 antigen
WO2006044294A2 (en) 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
IL151865A0 (en) 2000-03-31 2003-04-10 Genentech Inc Compositions and methods for detecting and quantifying gene expression
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002078766A2 (en) 2001-04-02 2002-10-10 Genentech, Inc. Combination therapy
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗ｃｄ４０モノクローナル抗体
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US7711492B2 (en) * 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
SI1682177T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2006125143A2 (en) * 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
ATE485057T1 (de) 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
JP5904569B2 (ja) 2005-06-08 2016-04-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療を受けている患者の同定、判定および処置のための方法
JP2009508484A (ja) 2005-09-16 2009-03-05 バイオベイター・テクノロジーズ・アクチボラゲット アレルゲン性タンパク質の同定のためのインビトロアッセイ
DE102005052384B4 (de) 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
US7527774B2 (en) 2005-12-22 2009-05-05 Basf Catalysts Llc Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms
EP1987161A4 (en) 2006-01-20 2009-06-24 Univ Mcgill METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
US9617600B2 (en) 2009-04-18 2017-04-11 Genentech, Inc. Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044294A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Method of therapy for cancers expressing the cd40 antigen
WO2006044294A2 (en) 2004-10-14 2006-04-27 Eli Lilly And Company Human protein c analogs
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of immunology. 2001, vol. 166, no. 1, pp. 89-94.

Also Published As

Publication number Publication date
CN101910414A (zh) 2010-12-08
US20110104671A1 (en) 2011-05-05
JP5730576B2 (ja) 2015-06-10
EP2222875A1 (en) 2010-09-01
BRPI0820707A2 (pt) 2015-06-16
AU2008323701B2 (en) 2015-03-26
CN101910414B (zh) 2016-01-13
KR20100095564A (ko) 2010-08-31
MX2010005080A (es) 2010-07-28
US9068230B2 (en) 2015-06-30
JP2014057588A (ja) 2014-04-03
JP2011504102A (ja) 2011-02-03
IL205391A (en) 2015-08-31
EP2222875B1 (en) 2014-08-20
WO2009062125A1 (en) 2009-05-14
CA2704499C (en) 2020-03-10
IL205391A0 (en) 2010-12-30
AU2008323701A1 (en) 2009-05-14
CA2704499A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
KR101620642B1 (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
AU2019201577B2 (en) Cancer diagnostics using biomarkers
KR101787768B1 (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
ES2374954T3 (es) Variaciones genéticas asociadas con tumores.
AU2014346788B2 (en) Method for subtyping lymphoma types by means of expression profiling
CN101370946B (zh) 用于使生物标志产物水平与疾病相关联的方法和装置
KR102023584B1 (ko) 위장관췌장 신경내분비 신생물 (GEP-NENs)의 예측 방법
AU2013277971B2 (en) Molecular malignancy in melanocytic lesions
US12404557B2 (en) Biomarkers predictive of anti-immune checkpoint response
AU2015257483B2 (en) Biomarkers and combinations thereof for diagnosising tuberculosis
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US20030175736A1 (en) Expression profile of prostate cancer
KR20110015409A (ko) 염증성 장 질환에 대한 유전자 발현 마커
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
KR20140140069A (ko) 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
WO2021162981A2 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
AU2016377391B2 (en) Triage biomarkers and uses therefor
CA2666057C (en) Genetic variations associated with tumors
CN101111768A (zh) 肺癌预后
KR20070099564A (ko) 급성 골수성 백혈병 환자를 평가하는 방법
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
CN115698719A (zh) 用于癌症免疫疗法的方法和组合物
US20030175761A1 (en) Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100604

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131105

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150515

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160226

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160504

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160504

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20190515

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20190515

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240424

Start annual number: 9

End annual number: 9